Search in:

Advanced search

International Journal of Chronic Obstructive Pulmonary Disease Volume 11, 2016 - Issue

Submit an article Journal homepage

Open access

Views

CrossRef citations to date

Altmetric

Original Research

Prevention of clinically important deteriorations in COPD with umeclidinium/vilanterol

Dave Singh1 Medicines Evaluation Unit, University of Manchester, University Hospital of South Manchester NHS Foundation Trust, Manchester, UKCorrespondence[email protected]

M Reza Maleki-Yazdi2 Division of Respiratory Medicine, Women’s College Hospital, University of Toronto, ON, Canada

Lee Tombs3 Precise Approach LTD, London UK

Ahmar Iqbal4 Respiratory Medical Franchise, GSK, Research Triangle Park, NC, USA

William A Fahy5 Respiratory Medicines Development Centre, GSK, Stockley Park, Middlesex, UK

Ian Naya5 Respiratory Medicines Development Centre, GSK, Stockley Park, Middlesex, UK

Pages 1413-1424 | Published online: 24 Jun 2016

Cite this article
CrossMark

Full Article
Figures & data
References
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF

References

GOLDGlobal strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease2015 Available from: http://www.goldcopd.com/Accessed August 12, 2015
Google Scholar
DransfieldMTBaileyWCraterGEmmettAO’DellDMYawnBDisease severity and symptoms among patients receiving monotherapy for COPDPrim Care Respir J2011201465320886200
PubMedGoogle Scholar
SinghDNew combination bronchodilators for chronic obstructive pulmonary disease: current evidence and future perspectivesBr J Clin Pharmacol201579569570825377687
PubMed Web of Science ®Google Scholar
DonohueJFMaleki-YazdiMRKilbrideSMehtaRKalbergCChurchAEfficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPDRespir Med2013107101538154623830094
PubMed Web of Science ®Google Scholar
CelliBCraterGKilbrideSOnce-daily umeclidinium/vilanterol 125/25 mcg in COPD: a randomized, controlled studyChest2014145598199124385182
PubMed Web of Science ®Google Scholar
Maleki-YazdiMRKaelinTRichardNZvarichMChurchAEfficacy and safety of umeclidinium/vilanterol 62.5/25 mcg and tiotropium 18 mcg in chronic obstructive pulmonary disease: results of a 24-week, randomized, controlled trialRespir Med2014108121752176025458157
PubMed Web of Science ®Google Scholar
ObaYSarvaSTDiasSEfficacy and safety of long-acting beta-agonist/long-acting muscarinic antagonist combinations in COPD: a network meta-analysisThorax2016711152526490732
PubMed Web of Science ®Google Scholar
DecramerMAnzuetoAKerwinEEfficacy and safety of umecli-dinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trialsLancet Respir Med20142647248624835833
PubMed Web of Science ®Google Scholar
BatemanEDFergusonGTBarnesNDual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE studyEur Respir J20134261484149423722616
PubMed Web of Science ®Google Scholar
SilerTMKerwinESousaARDonaldAAliRChurchAEfficacy and safety of umeclidinium added to fluticasone furoate/vilanterol in chronic obstructive pulmonary disease: results of two randomized studiesRespir Med201510991155116326117292
PubMed Web of Science ®Google Scholar
JonesPWSt George’s Respiratory Questionnaire: MCIDCOPD200521757917136966
PubMedGoogle Scholar
DonaldsonGCSeemungalTABhowmikAWedzichaJARelationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary diseaseThorax2002571084785212324669
PubMed Web of Science ®Google Scholar
SchmidtSAJohansenMBOlsenMThe impact of exacerbation frequency on mortality following acute exacerbations of COPD: a registry-based cohort studyBMJ Open2014412e006720
PubMed Web of Science ®Google Scholar
SinDDManSFChronic obstructive pulmonary disease as a risk factor for cardiovascular morbidity and mortalityProc Am Thorac Soc20052181116113462
PubMedGoogle Scholar
SinDDWuLManSFThe relationship between reduced lung function and cardiovascular mortality: a population-based study and a systematic review of the literatureChest200512761952195915947307
PubMed Web of Science ®Google Scholar
TockmanMSPearsonJDFlegJLRapid decline in FEV1. A new risk factor for coronary heart disease mortalityAm J Respir Crit Care Med19951512 Pt 13903987842197
PubMed Web of Science ®Google Scholar
JonesPWLamarcaRChuecosFCharacterisation and impact of reported and unreported exacerbations: results from ATTAINEur Respir J20144451156116525234803
PubMed Web of Science ®Google Scholar
WilkeSJonesPWMullerovaHOne-year change in health status and subsequent outcomes in COPDThorax201570542042525782757
PubMed Web of Science ®Google Scholar
DonohueJFMinimal clinically important differences in COPD lung functionCOPD20052111112417136971
PubMedGoogle Scholar
WestwoodMBourbeauJJonesPWCerulliACapkun-NiggliGWorthyGRelationship between FEV1 change and patient-reported outcomes in randomised trials of inhaled bronchodilators for stable COPD: a systematic reviewRespir Res2011124021477298
PubMed Web of Science ®Google Scholar
CelliBRMacNeeWStandards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paperEur Respir J200423693294615219010
PubMed Web of Science ®Google Scholar
WitekTJJrMahlerDAMinimal important difference of the transition dyspnoea index in a multinational clinical trialEur Respir J200321226727212608440
PubMed Web of Science ®Google Scholar
Garcia-RioFRojoBCasitasRPrognostic value of the objective measurement of daily physical activity in patients with COPDChest2012142233834622281798
PubMed Web of Science ®Google Scholar
VaesAWGarcia-AymerichJMarottJLChanges in physical activity and all-cause mortality in COPDEur Respir J20144451199120925063247
PubMed Web of Science ®Google Scholar
WaschkiBSpruitMAWatzHPhysical activity monitoring in COPD: compliance and associations with clinical characteristics in a multicenter studyRespir Med2012106452253022118987
PubMed Web of Science ®Google Scholar
WatzHWaschkiBMeyerTMagnussenHPhysical activity in patients with COPDEur Respir J200933226227219010994
PubMed Web of Science ®Google Scholar
SinghDZhuCQSharmaSChurchAKalbergCJDaily variation in lung function in COPD patients with combined albuterol and ipratropium: results from a 4-week, randomized, crossover studyPulm Pharmacol Ther201531859125197005
PubMed Web of Science ®Google Scholar

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Prevention of clinically important deteriorations in COPD with umeclidinium/vilanterol

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Prevention of clinically important deteriorations in COPD with umeclidinium/vilanterol

References

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date